HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andres Maldonado reiterates a Buy rating on Ikena Oncology (NASDAQ:IKNA) and maintains an $18 price target.
May 24, 2023 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andres Maldonado reiterates a Buy rating on Ikena Oncology and maintains an $18 price target.
The reiteration of a Buy rating and maintenance of an $18 price target by HC Wainwright & Co. analyst Andres Maldonado indicates a positive outlook for Ikena Oncology's stock. This news is directly related to IKNA and is important for investors as it suggests potential upside in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100